Pelvic Exenteration for Advanced Nonrectal Pelvic Malignancy
Conclusion:
Pelvic exenteration remains an important treatment in selected patients with advanced or recurrent nonrectal pelvic malignancy. The range in 3-year overall survival following R0 resection (40%–59%) reflects the diversity of tumor types.
Source: Annals of Surgery - Category: Surgery Tags: ESA PAPERS Source Type: research
More News: Anal Cancer | Bladder Cancer | Cancer | Cancer & Oncology | Cervical Cancer | Endometrial Cancer | Neoadjuvant Therapy | Ovarian Cancer | Ovaries | Sarcomas | Surgery | Urology & Nephrology